Ratings HealthCare Global Enterprises Limited Bombay S.E.

Equities

HCG

INE075I01017

Delayed Bombay S.E. Other stock markets 03:24:13 07/05/2024 pm IST			5-day change	1st Jan Change
365.1 ^INR	-1.91%		-0.30%	-0.15%

02/05	Temasek May Bid for CVC's 60% Stake in Healthcare Global	CI
08/03	HealthCare Global Enterprises Limited acquired remaining 49.5% stake in Hcg Eko Oncology LLP from Eko-diagnostic Pvt Ltd for INR 200 million.	CI

Summary

Overall, the company has poor fundamentals for a medium to long-term investment strategy.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 130.83 times its estimated earnings per share for the ongoing year.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The company is highly valued given the cash flows generated by its activity.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
HEALTHCARE GLOBAL ENTERPRISES LIMITED	-0.15%	622M		B
HCA HEALTHCARE, INC.	+14.55%	81.21B		C+
CVS HEALTH CORPORATION	-29.12%	70.26B		B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+11.76%	29.62B		C+
LABORATORY CORPORATION OF AMERICA HOLDINGS	-11.55%	16.95B		B
FRESENIUS SE & CO. KGAA	-1.25%	16.91B		A-
QUEST DIAGNOSTICS INCORPORATED	-1.62%	15.07B		A-
FRESENIUS MEDICAL CARE AG	-2.42%	12.52B		A-
PURE HEALTH HOLDING	-31.40%	11.92B	-	-
REDE D'OR SÃO LUIZ S.A.	-5.39%	12.1B		B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes